Targacept, Inc. is a biopharmaceutical company engaged in the development of novel NNR Therapeutics™ for the treatment of various diseases and disorders of the nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.
An estimated 4.7 million people in the world's seven major pharmaceutical markets suffer from schizophrenia. For a large portion of those patients, negative symptoms and cognitive dysfunction in schizophrenia remain an umet medical need. READ MORE.
Overactive bladder (OAB) poses a significant reduction in the quality of life for patients who suffer from the disorder. READ MORE about our development plans for TC-5214 in this indication.